Guardian Pharmacy Services (NYSE:GRDN) Major Shareholder Equity Fund L.P. Cardinal Sells 275,728 Shares

Guardian Pharmacy Services, Inc. (NYSE:GRDN) major shareholder Equity Fund L.P. Cardinal sold 275,728 shares of the stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $29.68, for a total transaction of $8,183,607.04. Following the transaction, the insider owned 345,123 shares in the company, valued at approximately $10,243,250.64. The trade was a 44.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Guardian Pharmacy Services Trading Down 2.8%

Shares of GRDN opened at $36.52 on Thursday. Guardian Pharmacy Services, Inc. has a 12 month low of $19.17 and a 12 month high of $38.12. The firm’s 50 day moving average is $32.62 and its 200-day moving average is $29.87. The stock has a market capitalization of $2.31 billion, a PE ratio of 47.43 and a beta of 0.86.

Guardian Pharmacy Services (NYSE:GRDN) last issued its quarterly earnings results on Wednesday, March 11th. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.10. The business had revenue of $397.62 million during the quarter, compared to analysts’ expectations of $390.04 million. Guardian Pharmacy Services had a return on equity of 31.64% and a net margin of 3.40%.The firm’s revenue for the quarter was up 17.4% on a year-over-year basis. Equities research analysts predict that Guardian Pharmacy Services, Inc. will post 0.87 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently issued reports on GRDN shares. Raymond James Financial reissued an “outperform” rating and set a $40.00 target price on shares of Guardian Pharmacy Services in a report on Thursday, March 12th. Oppenheimer boosted their price target on Guardian Pharmacy Services from $35.00 to $38.00 and gave the company an “outperform” rating in a research note on Thursday, March 12th. Stephens upped their price objective on shares of Guardian Pharmacy Services from $35.00 to $36.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 14th. Truist Financial increased their price objective on shares of Guardian Pharmacy Services from $34.00 to $38.00 and gave the stock a “buy” rating in a research note on Thursday, March 12th. Finally, UBS Group reissued a “buy” rating on shares of Guardian Pharmacy Services in a report on Thursday, March 12th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Guardian Pharmacy Services currently has a consensus rating of “Buy” and a consensus target price of $38.00.

Key Headlines Impacting Guardian Pharmacy Services

Here are the key news stories impacting Guardian Pharmacy Services this week:

• Neutral Sentiment: Market writeup noting broad insider activity at Guardian Pharmacy Services; useful context but not new filings. TipRanks article
• Negative Sentiment: Director Thomas J. Salentine, Jr. sold 3,570,677 shares at an average $29.68 (≈$106.0M). Filing: SEC filing
• Negative Sentiment: Director William E. Bindley sold 3,570,677 shares at $29.68 (≈$106.0M). Filing: SEC filing
• Negative Sentiment: Director John Ackerman sold 1,103,364 shares at $29.68 (≈$32.7M). Filing: SEC filing
• Negative Sentiment: Director/officer Fred Burke sold 671,432 shares at $29.68 (≈$19.9M). Filing: SEC filing
• Negative Sentiment: Insider Kendall Forbes sold 346,672 shares at $29.68 (≈$10.3M). Filing: SEC filing
• Negative Sentiment: Insider David K. Morris sold 187,855 shares at $29.68 (≈$5.6M). Filing: SEC filing
• Negative Sentiment: Major shareholder Equity Fund L.P. Cardinal sold 275,728 shares at $29.68 (≈$8.2M), a ~44% reduction in its stake. Filing: SEC filing

Institutional Investors Weigh In On Guardian Pharmacy Services

Several institutional investors and hedge funds have recently added to or reduced their stakes in GRDN. State of Alaska Department of Revenue acquired a new stake in shares of Guardian Pharmacy Services in the 3rd quarter valued at $30,000. Ameritas Investment Partners Inc. raised its holdings in shares of Guardian Pharmacy Services by 26.5% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,647 shares of the company’s stock worth $43,000 after buying an additional 345 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Guardian Pharmacy Services during the 2nd quarter worth $43,000. Police & Firemen s Retirement System of New Jersey lifted its position in shares of Guardian Pharmacy Services by 76.8% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 2,444 shares of the company’s stock worth $52,000 after buying an additional 1,062 shares during the last quarter. Finally, State of Wyoming bought a new stake in shares of Guardian Pharmacy Services during the 2nd quarter worth $58,000.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.